Weight decline in patients switching from olanzapine to quetiapine

Schizophrenia Research

Volumn 70, Issue 1, 2004, Pages 57-62

  Gupta, Sanjay ^a,d,e   Masand, Prakash S ^b   Virk, Shubdeep ^c   Schwartz, Thomas ^c   Hameed, Ahmed ^c   Frank, Bradford L ^a,d   Lockwood, Kari ^d  

^a UNIVERSITY AT BUFFALO   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^d Global Research and Consulting   (United States)

^e NONE   (United States)

Author keywords

Olanzapine; Quetiapine; Switch; Weight gain

Indexed keywords

OLANZAPINE; QUETIAPINE;

ADULT; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; LABORATORY TEST; MALE; METABOLIC PARAMETERS; METABOLISM; NEGATIVE SYNDROME; OPEN STUDY; PARKINSONISM; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

BASAL GANGLIA DISEASES; BENZODIAZEPINES; BODY WEIGHT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; WEIGHT LOSS;

EID: 3142756414     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2003.09.016     Document Type: Conference Paper

References (36)

1. Ackerman S., Nolan J. Bodyweight gain-induced by psychotropic drugs. CNS Drugs. 9:1998;135-151
2. Allison D.B., Casey D.E. Antipsychotic-induced weight gain: a review of the literature. J. Clin. Psychiatry. 62(Suppl. 7):2001;22-31
3. Allison D.B., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. 156:1999;1686-1696
4. Arato M., et al. 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int. Clin. Psychopharmacol. 17:2002;207-215
5. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;American Psychiatric Press, Washington, DC
6. Awad A.G., et al. Patient attitude after switch to ziprasidone from other antipsychotics. Presented at: Association of European Psychiatrists; May 5; Stockholm, Sweden:2002
7. Basson B.R. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J. Clin. Psychiatry. 62:2001;231-238
8. Brecher M., et al. The long-term effect of quetiapine monotherapy on weight in patients with schizophrenia. Int. J. Psychiatry Clin. Pract. 4:2000;287-291
9. Calle E.E. Body-mass index and mortality in a prospective cohort of U.S. adults. N. Engl. J. Med. 341:1999;1097-1105
10. Carnahan R.M. Ziprasidone, a new atypical antipsychotic drug. Pharmacotherapy. 21:2001;717-730
11. Casey D., et al. Switching to aripiprazole monotherapy. Int. J. Neuropsychopharmacol. 5:2002;S187. (suppl)
12. Czobor P., et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J. Clin. Psychopharmacol. 22:2002;244-251
13. Ganguli R. Weight gain associated with antipsychotic drugs. J. Clin. Psychiatry. 60(Suppl. 21):1999;20-24
14. Gupta S., et al. Olanzapine-induced weight gain. Ann. Clin. Psychiatry. 10:1998;39
15. Gupta S., et al. Olanzapine: weight gain and therapeutic efficacy. J. Clin. Psychopharmacol. 19:1999;273-275
16. Jody D., et al. Meta-analysis of weight effects with aripiprazole. Presented at the 23rd Collegium Internationale Neurpsychopharmacologicum Congress meeting; June 23rd 27th, 2002, Montreal, Canada:2002
17. Jones A., et al. Weight changes in patients treated with quetiapine. Presented at: American Psychiatric Association Annual Meeting; May 13-18, Chicago, IL. 2000
18. Kasper S., Muller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin. Pharmacother. 1:2000;783-801
19. Keck P.E. Jr., et al. Ziprasidone: a new atypical antipsychotic. Expert Opin. Pharmacother. 2:2001;1033-1042
20. Masand P.S. Weight gain associated with atypical antipsychotics. J. Psychotic Disord. 11:1998;4-6
21. Masand P.S. Weight gain associated with psychotropic drugs. Expert. Opin. Pharmacother. 1:2000;377-389
22. Masand P.S., Gupta S. Long-term adverse effects of atypical antipsychotics. Psychiatr. Prakt. 6:2000;299-309
23. McIntyre R., et al. 40th American College of Neuropsychopharmacology Annual Meeting, Waikaloa Village, Hawaii, December 8-12:2001
24. Must A. The disease burden associated with overweight and obesity. JAMA. 282:1999;1523-1529
25. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 28(Suppl 1):2003;83-96
26. National Task Force on the Prevention and Treatment of Obesity Overweight, obesity, and health risk. Arch. Intern. Med. 160:2000;898-904
27. Nemeroff C.B. Dosing the antipsychotic medication olanzapine. J. Clin. Psychiatry. 58(Suppl 10):1997;45-49
28. Pfizer, 2002. Geodon. Full prescribing information.
29. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Clinical Practice Recommendations. vol. 24, Suppl. 1:2001;American Diabetes Association
30. 2C receptor gene polymorphism. Lancet. 359:2002;2086-2087
31. Simpson G., et al. Proceedings of the American Psychiatric Association Annual Meeting May 13-18, Chicago, IL:2000
32. Stimmel G.L. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin. Ther. 24:2002;21-37
33. Wang G.J., et al. Brain dopamine and obesity. Lancet. 357:2001;354-357
34. Wetterling T., Mussigbrodt H.E. Weight gain: side effect of atypical neuroleptics? J. Clin. Psychopharmacol. 19:1999;316-321
35. Wirshing D.A., et al. Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychiatry. 60:1999;358-363
36. Worrel J.A. Atypical antipsychotic agents: a critical review. Am. J. Health-Syst. 57:2000;238-255